These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37661408)

  • 1. Comparison of the Speed of Enrollment for Clinical Trials Conducted by Japanese and Global Pharmaceutical Companies.
    Maeda H; Yamanoi M; Fukuda Y; Inaba Y
    Biol Pharm Bull; 2023; 46(9):1289-1295. PubMed ID: 37661408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Driving clinical study efficiency by using a productivity breakdown model: comparative evaluation of a global clinical study and a similar Japanese study.
    Takahashi K; Sengoku S; Kimura H
    J Clin Pharm Ther; 2011 Feb; 36(1):87-98. PubMed ID: 21198723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.
    Okuyama R
    Biol Pharm Bull; 2023; 46(5):718-724. PubMed ID: 37121698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the registration of clinical trials in UMIN-CTR from 2 June 2005 to 1 June 2010 - focus on Japan domestic, academic clinical trials.
    Tang W; Fukuzawa M; Ishikawa H; Tsutani K; Kiuchi T
    Trials; 2013 Oct; 14():333. PubMed ID: 24124926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations.
    Dombernowsky T; Haedersdal M; Lassen U; Thomsen SF
    Trials; 2019 Dec; 20(1):708. PubMed ID: 31829234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of awarding compensation for claims of injuries related to clinical trials by pharmaceutical companies in Japan: a questionnaire survey.
    Kurihara C; Kusuoka H; Ono S; Kakee N; Saito K; Takehara K; Tsujide K; Nabeoka Y; Sakuhiro T; Aoki H; Morishita N; Suzuki C; Kachi S; Kondo E; Komori Y; Isobe T; Kageyama S; Watanabe H
    PLoS One; 2014; 9(1):e84998. PubMed ID: 24416332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
    Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
    Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chapter 1. A contemporary history of the Japanese pharmaceutical industry (1980-2010). A contemporary history of the Japanese Pharmaceutical Industry (1980-2010) Task Force].
    Yakushigaku Zasshi; 2014; 49(1):18-38. PubMed ID: 25272635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2024 Jul; 58(4):766-772. PubMed ID: 38652349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Differences During the ICH Regulatory Consultation Process Between the EU, US, and Japan.
    Torqui A; Macau AM
    Ther Innov Regul Sci; 2018 Jul; 52(4):438-441. PubMed ID: 29714552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany.
    Shibata S; Uemura R; Suzuki T
    Ther Innov Regul Sci; 2016 Mar; 50(2):221-227. PubMed ID: 30227003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.